Cell line · CVCL_0201
Papers97
1 to 20 of 97
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Exosomal circ_0000387 Is Associated With Ovarian Cancer Metastatic Regulation Through IGF2BP3-Related Signalling and Endothelial VWF Responses. | J Biochem Mol Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nuclear localization of the glutaminyl-tRNA synthetase QARS reveals its role in DNA damage response in ovarian cancer. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2-Dependent MDSC Recruitment. | Cancer Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. | Adv Biol (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Indoleamine 2,3-dioxygenase 1 inhibition reverses cancer-associated fibroblast-mediated immunosuppression in high-grade serous ovarian cancer. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Adenosine-to-inosine editing of miR-200b-3p is associated with the progression of high-grade serous ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| 3β-Hydroxysterol Δ24-Reductase Promotes Ovarian Cancer Progression by Activating the TGF-β1/Smad2/3 Signaling Pathway. | Oncol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer. | Open Med (Wars) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tissue-dependent mechanosensing by cells derived from human tumors. | NPJ Biol Phys Mech | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mortalin and PINK1/Parkin-Mediated Mitophagy Represent Ovarian Cancer-Selective Targets for Drug Development. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0201/papers